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Lithium remains the gold standard for the treatment of Bipolar Disorder (BD); however, its use has 
declined over the years mainly due to side effects and the subjective experience of cognitive numbness 
reported by patients.  In the present study, we aim to methodically test the effects of lithium on 
neurocognitive functioning in the largest single cohort (n=262) of BD patients reported to date by 
harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy.  
At the cross-sectional level, Multivariate Analysis of Covariance (MANCOVA) was conducted to examine 
potential group differences across neurocognitive tests [California Verbal Learning Test (CVLT trials 1-
5,CVLT delayed recall), Wechsler Digit Symbol, Trail-making Test parts A and B (TMT-A; TMT-B), and a 
global cognition index). At the longitudinal level, on a subset of patients (n=88) who achieved mood 
stabilization with lithium monotherapy, we explored the effect of lithium treatment across time on 
neurocognitive functioning.   
There were no differences at baseline between BD patients that were taking lithium compared to those 
that were not. At follow-up a significant neurocognitive improvement in the global cognitive index score 
[F=31.69; p<0.001], CVLT trials 1-5 [F=29.81; p<0.001], CVLT delayed recall [F=15.27; p<0.001], and TMT-
B [F=6.64, p=0.012] was detected. 
The cross-sectional and longitudinal (on a subset of 88 patients) investigations suggest that lithium may 
be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not 








Neurocognitive impairment is common in patients with bipolar disorder (BD), even during periods of 
affective remission [1]. Persistent deficits in attention, verbal learning/memory, and some executive 
functions [2] have been directly linked to functional disability [3,4], making these deficits particularly 
relevant to patients’ quality of life. The nature of these impairments is not well-understood, with recent 
data suggesting significant heterogeneity in outcome [5]. Early evidence suggests that cognitive 
impairments in BD are caused by a number of factors, stemming both from abnormal early 
development/genetic predisposition [6,7], medical/cardiovascular comorbidities [8,9], and from 
neurodegenerative processes [10] related to the expression of the disorder and/or to its treatment. The 
potential adverse effects of psychotropic medications have long been described anecdotally but 
generally have not been systematically characterized. This is of particular significance as it is one of the 
more modifiable aspects contributing to reported cognitive difficulties in patients with BD. 
 
Among the plethora of psychotropic agents now available to treat differing aspects of BD, lithium has 
been in use the longest and it remains a first-line treatment option because of its efficacy in long-term 
prophylaxis and its positive effects on suicide risk [11,12]. Despite a number of potentially serious 
adverse effects on renal and endocrine function [13], patients frequently complain of weight gain and a 
subjective experience of neurocognitive dulling  [14,15].  Importantly, BD patients list cognitive 
dysfunction, manifested by mental slowness, as the side effect most likely to precipitate lithium 
nonadherence [16].   While BD patients’ own perception of their cognitive abilities has been 
demonstrated to be relatively discordant with objective measures of neurocognitive functioning [17], 
these perceived side effects may nonetheless result in lithium non-compliance and ultimately mood de-
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stabilization. There is a surprising dearth of controlled data evaluating the objective cognitive side 
effects of lithium treatment in BD. 
 
A relatively recent meta-analysis by Wingo and colleagues (2009) summarized the existing literature on 
the cognitive effects of lithium, which to date included a total of 213 healthy controls and 326 affective 
disorder patients (73% bipolar disorder; 19.6% recurrent unipolar; 7.4% cycloid of schizoaffective). The 
on-lithium group consisted of 276 individuals  (105 healthy volunteers; 171 affective disorder patients) 
versus 263 individuals who were not taking lithium (108 healthy volunteers; 155 affective disorder 
patients) [18]. When analyzed together, those subjects taking lithium showed minor deficits on verbal 
learning and creativity as compared with those not taking lithium. When grouped by diagnostic status, 
the healthy controls exposed to short-term lithium treatment (mean duration of 2.5 weeks) did not 
differ from healthy subjects who were not exposed to lithium. In contrast, affective disorder patients on 
longer –term lithium treatment (mean duration of 47 months) showed mild deficits on verbal learning 
and creativity and moderate impairments on psychomotor speed relative to patients not taking lithium 
[18]. The authors concluded that lithium use over a longer duration is associated with mild 
neurocognitive deficits; however, several limitations to interpreting these data were acknowledged 
including a lack of information on relevant illness parameters (e.g. number of prior manias; history of 
psychosis; and importantly concomitant psychotropic medications).  In addition to these limitations, 
prior studies of lithium and cognition have generally not accounted for dosage and plasma lithium 
levels, treatment parameters that may be relevant to cognitive outcome. 
 
Despite the results of this single meta-analysis, data on cognitive outcomes after lithium exposure are 
equivocal and there remains a lack of clarity around lithium’s exact mechanism of action [19]. Indeed, 
many of the known intracellular and molecular effects of lithium are suggestive of beneficial effects on 
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brain structure and function [19], which should intuitively result in pro-cognitive effects.  There is in fact 
some evidence to support a neuroprotective role for lithium in reducing the incidence of dementia in 
patients with BD [20] as well as some early longitudinal data that evidence no clear cognitive change 
over time in BD patients treated with lithium [21,22].  
 
In the current study, we systematically tested the effects of lithium treatment on neurocognitive 
functioning in patients with BD in the largest single cohort reported to date by harnessing the power of 
a multi-site, , ongoing pharmacogenetic trial of lithium monotherapy. We first assessed the cognitive 
effects of lithium treatment cross-sectionally in 262 BD subjects and then followed a subset of these 
patients (n=88) who achieved mood stabilization after being optimized on lithium monotherapy, 
allowing for longitudinal analyses of this cohort. 
 
MATERIALS AND METHODS 
This study is an 11-site, prospective, non-randomized, open trial of lithium designed to collect a very 
large cohort of patients with bipolar I disorder to be treated with lithium monotherapy to promote 
relapse prevention. The primary purpose of this study was to identify pharmacogenetic predictors of 
lithium response using genome-wide association study (GWAS). Several biological and clinical predictors 
of treatment response are included in the design. Here, we are focusing on the neurocognitive data 
collected in the context of this trial. A full description of the methods of this trial can be found in 
Oedegaard et al. 2016 [23]. The study was conducted in accordance with the Declaration of Helsinki and 
the protocol was approved by local IRBs at all sites in the US and Canada, as well as the Ethics 
Committee and Health Authorities in Norway. All subjects provided written informed consent prior to 




Briefly, patients were systematically diagnosed using the DIGS (Diagnostic Interview for Genetic Studies; 
[24]. Each patient was categorized at baseline with regard to prior lithium exposure into one of four 
groups: 1) clinically stable (see details below) patients who were currently taking lithium monotherapy 
(current lithium monotherapy patients- CLM); 2) clinically stable patients who were currently taking 
lithium plus some additional psychotropic medication(s) (current lithium polytherapy patients- CLP); 3) 
patients who were currently taking lithium but were not clinically stable (current lithium but unstable 
patients - CLU); and 4) patients who were not taking  lithium (not currently on lithium patients- NCL).  
Neurocognitive testing was completed for the full sample at baseline. Time 2 testing was only completed 
for a subset of the subjects who entered the maintenance phase of the study (the exact timing of which 
varied dependent upon clinical response parameters). Specifically, after lithium monotherapy treatment 
was initiated at the baseline visit, dosing was optimized over a variable timeframe (up to 3 months of 
open stabilization phase) until the patient achieved a rating of 1 (normal, not ill), or 2 (minimally ill) on 
the Clinical Global Impressions of Severity Scale for Bipolar Disorder (CGI-S-BP Overall Bipolar Illness) for 
4 out of 5 preceding weeks (observation phase). Once this milestone was achieved, cognitive testing was 
repeated and patients entered a two-year follow-up period on lithium monotherapy. Subjects who did 
not respond adequately to lithium monotherapy were treated as per protocol (e.g. dropped from the 
study, switched to valproate or switched to treatment as usual) but were not tested at a second time-
point.  
 
Clinical and Neurocognitive Measures  
To evaluate current severity of mood symptoms clinician-administered and self-report measures were 
used; the Clinician Administered Rating Scale for Mania (CARS-M;[25]) and the Montgomery Asberg 
Depression Rating Scale (MADRS;[26]); the Quick Inventory of Depressive Symptomatology Self-Report 
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(QIDS-SR 16;[27]) were completed at each visit.  Mood ratings were conducted at each visit to account 
for current symptom severity and quality of life self-reports were also completed. 
 
Neurocognitive performance was assessed using the following tasks: Trail Making Test – part A (TMT-A; 
processing speed), Trail Making Test – part B (TMT-B; executive function and set-shifting); WAIS-III Digit 
Symbol subtest (visual scanning and psychomotor speed); Controlled Oral Word Association Test 
(COWAT; phonemic fluency); California Verbal Learning Test (CVLT) Trials 1-5 total and CVLT delayed 
recall (verbal learning and memory). For a detailed description of the cognitive measures please refer to 
Strauss et al [28]. An estimate of premorbid IQ was obtained using the Wide Range Achievement Test-
3rd edition-Reading subtest (WRAT-3; [29]). Raw scores from each measure were used in analyses but z-
scores were calculated using the full BD sample (within sample z-scores) for purposes of graphic 
representation on a uniform scale and in order to provide a basis for calculating the global cognition 
index.  
 
A global cognitive index was obtained by calculating an unweighted average of all of the z-scores from 




Cross-sectional analyses focused on lithium status at baseline. We first compared subjects that were on 
lithium at baseline (Li+yes) versus those subjects that were not on lithium (Li+no) across a range of 
clinical and demographic characteristics using Analysis of Variance (ANOVA) or Chi-square where 
appropriate. A series of univariate analyses was conducted (covarying for age and current depressive 
and manic symptoms as measured by the MADRS and CARS-M respectively) to examine potential group 
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differences across each of the cognitive tests individually. This was done instead of a multivariate 
ANOVA to optimize the number of subjects included in each analysis (due to scattered missing 
datapoints on different measures).  The next level of cross-sectional analyses focused on the more 
specific subgrouping of the patients at baseline. As noted above, patients were categorized as follows at 
baseline: 1) clinically stable currently taking lithium monotherapy (CLM); 2) clinically stable currently 
taking lithium polytherapy (CLP); 3) those taking lithium but clinically unstable (CLU); and 4) those who 
were not currently taking lithium (NCL).  These four groups were compared in terms of clinical, 
demographic and cognitive characteristics using the same approach as above.  
 
Next, using the prospective sample of patients who were optimized on lithium monotherapy as part of 
this study, we began to address several of these limitations using longitudinal analyses.  
 
 
Prospective (longitudinal) analysis 
A series of Repeated Measures Analysis of Covariance (ANCOVA) models were used to explore the effect 
of lithium treatment across time for each of the neurocognitive tests. We did not include a between-
subjects fixed factor, as all patients were treated with lithium monotherapy; cognitive performance 
(CVLT trial 1-5, CVLT delayed recall, Digit Symbol, TMT-A, TMT-B, and a global cognitive index) at 
baseline and at follow-up served as the within-subjects variables. Covariates included affective change 
scores (differences between depressive and manic symptoms at follow up and at baseline). Sensitivity 
analyses tested whether plasma lithium levels at follow-up contributed to cognitive change.   
 
In addition to repeated measures analyses in an effort to account for the lack of a placebo arm and to 
estimate reliable change over time, we calculated a reliable change index (RCI) for cognitive measures 
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showing evidence for change in ANCOVA models models [30]. This approach allows for the evaluation of 
whether a change over time in an individual’s score (e.g. baseline versus follow-up) is considered 
statistically significant. The RCI is represented as a ratio, the numerator is the observed change and the 
denominator is a standard measure of the expected difference.  Cognitive tests have the advantage of 
having good reliability data, which can be used as the denominator in RCI analyses. We selected the 
CVLT for RCI analyses in this study, as it has substantial reliability data published on it. We could not 
easily do the same for the global cognitive index but expect based upon the consistency of the findings 
that we would have found similar estimates of improvement at the individual level. As it is customary 
using the RCI, we report the percent of patients that showed reliable improvement, those who showed 




Full sample descriptive at baseline 
Two hundred sixty-two BD I patients entered the study; 122 were males (45.9%) and the mean age was 
42.7 years (SD=14.5). At baseline, there were no clinically relevant manic symptoms as assessed by the 
CARS-M (mean=5.4; SD=±7.0) while some mild depressive symptoms were noted on the MADRS 
(mean=11.9; SD=±11.4).  
 
Lithium yes/no at baseline 
Of the 262 subjects tested at baseline, 169 were taking lithium (Li/yes) and 93 were not on lithium 
(Li/no). There were statistically significant clinical and demographic differences when comparing BD 
patients who were on lithium with those who were not on lithium at baseline (Table 1). Subjects that 
were not taking lithium were younger (p=0.002), less likely to be white (p<0.001) and had more severe 
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current manic and depressive symptoms (both clinician-assessed and self-reported) than those subjects 
taking lithium (both significant at p<0.001; Table 1). Using these variables as covariates, when 
comparing Li/yes vs. Li/no subjects on neurocognition, we found no significant group differences for 
either the global cognitive index any of the or individual cognitive tests (Table 1). When controlling for 
age, race, and mood state (CARS-M and MADRS scales) there were no group differences between Li/yes 
and Li/no groups. Cognitive performance of the two groups is depicted in Fig 1.    
 
4 lithium subgroups at baseline 
Of the 262 subjects tested at baseline, 73 were on monotherapy (CLM), 44 were on polytherapy (CLP), 
52 were currently on lithium but clinically unstable (CLU) and 93 were not currently taking lithium (NCL). 
The cognitive profiles of these 4 groups are depicted in Fig 2. When comparing neurocognitive 
performance across groups, we found a significant effect of group on CVLT trials 1-5 [F (3,254) =3.370, 
p=0.019].  Post hoc comparisons revealed that the CLM subjects performed significantly better than all 
other groups on CVLT trials 1-5: CLP subjects (mean difference=.53, SE=.19; p=.005); CLU subjects (mean 
difference=.37, SE=.18; p=.04); NCL subjects (mean difference=.39, SE=.16; p=.01).   
 
Prospective results  
Eighty-eight BD I patients, baseline status (CLM N=22, CLP N=14, CLU N=21, NCL N=31), completed data 
at both baseline and, after the initiation of lithium monotherapy, at the time that the patient entered 
the maintenance phase of the study. The mean age of these patients was 40.9 (SD=±14.2), 37 were male 
(42%), 69 (78.4%) were white; and the average premorbid IQ was 103.1 (SD=±13.9). At baseline, the 
mean CARS-M score was 5.7 (SD=±8.9) which indicates an absence of clinically significant manic 
symptoms; the mean MADRS score was 10.5 (SD=±10.3) which falls within the range indicative of mild 
depression. To determine the representativeness of our prospective sample, we compared it to the full 
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cohort using baseline data. There were no statistically significant differences between the two groups in 
terms of demographic, clinical or cognitive characteristics.   
 
The average daily dosage of lithium at the time of the first neurocognitive assessment (in the subset of 
patients already taking lithium at entry) was 914.4 mg (SD=±365.3) and the mean plasma lithium levels 
at baseline in the same subset was 0.63 (SD = 0.27; range 0.1 – 2.2). At follow-up, the mean dosage was 
929.2 mg (SD=±356.0) and mean plasma lithium levels were 0.65 (SD = 0.22 range 0.1 – 1.4). The 
average duration between the first and the second neurocognitive assessment was 132.1 days 
(SD=±90.3) with a wide range (32 days to 485 days). This variability was due to the inter-individual 
differences in time to reach stabilization criteria. 
 
As expected, clinical improvement was noted on mania (5.7±8.9 vs 1.8±3.4, respectively at baseline and 
follow-up) and depression symptom scales (10.5±10.3 vs 4.7±5.4); therefore, these were included as 
covariates in RMANOVAs. When comparing cognitive performance at baseline vs. follow up, analyses 
revealed significant neurocognitive improvement in the global cognitive index score [F=31.69; p<0.001], 
CVLT trials 1-5 [F=29.81; p<0.001], CVLT delayed recall [F=15.27; p<0.001], and TMT-B [F=6.64, p=0.012]. 
None of the cognitive measures evidenced decline over time with lithium treatment. When plasma 
lithium levels drawn at follow-up were added as covariates, the main effect of level was non-significant 
for all analyses and cognitive results remained significant. 
 
Analyses calculating the reliable change index (RCI) were carried out for the CVLT indicating that 30.7% 
(27/88) of patients showed a reliable improvement on this task over time; 63.6% (56/88) of patients 




There were non-significant correlations between plasma lithium levels and cognition (global cognitive 




Lithium remains one of the most effective treatments for reducing relapse and preventing suicide in 
patients with bipolar disorder. There are several side effects that have limited its use by clinicians; 
primarily adverse effects on renal and endocrine functioning. A very common complaint noted by 
patients who are taking lithium is related to a subjective sense of neurocognitive dulling, which is often 
a trigger for treatment non-compliance. Despite substantial anecdotal evidence, very few systematic 
studies have addressed the cognitive side effects of lithium. Our study is not the first to do so; however, 
we have the advantage of the largest cross-sectional cohort collected to date with cognitive measures 
and lithium treatment status. Moreover, we tracked a relatively large subset of this sample as they 
transitioned from various treatment regimens to lithium monotherapy with longitudinal data available 
to address cognitive changes.  
 
Our results from both cross-sectional and longitudinal analyses broadly suggest that lithium treatment 
does not significantly impair neurocognitive functions in patients with bipolar disorder. Indeed, cross-
sectional analyses comparing 169 patients currently taking lithium with 93 patients not taking lithium 
did not reveal any significant group differences on neurocognitive tests (CVLT trials 1-5, CVLT delayed 
recall, Digit Symbol, TMT-A, and TMT-B) or on global cognition – even after controlling for demographics 
and current mood symptoms. We were also able to analyze longitudinal data from a subset of this 
cohort who received follow-up cognitive testing after being stabilized on lithium monotherapy. This was 
not a placebo-controlled trial so practice effects on cognitive measure cannot be fully controlled for; 
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however, performance across all cognitive tests improved over the course of treatment and RCI indices 
suggest a much larger proportion of patients improved (~31%) than would be expected (~3%) to reliably 
improve based upon the psychometrics of the measures. These proportions are contrasted with what 
has been reported in healthy individuals on the CVLT with a one-month lag in repeat testing [31], where 
only ~3% of individuals show reliable improvement and ~96% show no change. Although we cannot 
interpret this as a cognitive benefit, these data do suggest that lithium did not result in deleterious 
effects on cognition. 
 
These findings are largely consistent with early small-scale studies that reported no significant negative 
effects of lithium on memory functions over a 4 and 12- month follow-up [22] as well as over a 6-year 
interval [21]. More recent meta-analyses note mild impairments on measures of processing speed, 
verbal learning, and creativity in bipolar subjects who had been exposed to long-term lithium treatment 
(mean of 47 months); however, this was based solely upon cross-sectional comparisons with subjects 
not taking lithium and many of the participants were taking other psychotropic medications. In the same 
analysis, healthy subjects exposed to lithium over a shorter duration did not evidence any cognitive 
impairment. 
 
The exact mechanism of action that makes lithium an effective mood stabilizer is unknown; however, 
there is mounting evidence that it has neuroprotective effects [32] which may be related to lithium’s 
effects on neuronal homeostasis [33]. In preclinical studies of transgenic mice that over-express GSK-3β, 
chronic lithium treatment can reverse neuropathology associated with Alzheimer’s disease (tau 
phosphorylation and Aβ production) and improve memory deficits [34–37] via direct modulation of APP 
and inhibition of GSK-3β [38,39]. In addition, lithium has been shown to stimulate the expression of anti-
apoptotic proteins (e.g. Bcl-2) promoting neuronal survival [40] and stimulate the synthesis of 
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neurotrophic factors such as brain derived neurotrophic factor (BDNF) and vascular endothelial growth 
factor (VEGF) to promote hippocampal neurogenesis, synaptic plasticity, and long-term potentiation 
(LTP) [41]. Lithium also serves to modulate inflammatory processes by reducing pro-inflammatory 
cytokines and microglial activation in animal models of stroke [42]. Convergent data from clinical and 
neuroimaging studies support the myriad of beneficial effects seen at the cellular level. Registry data 
suggest that bipolar patients chronically treated with lithium are significantly less likely to develop 
dementia than patients taking other mood stabilizers or not taking medications [20,43].  Antioxidant and 
pro-BDNF effects have also been linked with lithium treatment response in BD patients [44] and in 
healthy subjects [45]. Neuroimaging studies support lithium’s neuroprotective effect, with data 
suggesting that long term lithium treatment is associated with increased volume of the hippocampus 
and amygdala and increased cortical thickness [46–50]. Taken together, data from preclinical, clinical, 
and neuroimaging-based studies strongly support lithium’s role in neuroprotection and our data are 
consistent with these findings.  
 
Overall, data derived from our large cohort of BD patients taking lithium suggest no deleterious effects 
on neurocognitive functioning, despite the frequent subjective complaints of cognitive dulling noted by 
patients treated with this agent. It might be speculated that the subjective self-reports of cognitive 
impairment after starting lithium are related more directly to stabilization of affective symptoms that 
may be deemed as positive (e.g. hypomania) to the patient. There are some limitations to our work 
including the lack of a placebo-control; however, this was a real-world trial with a focus on real-world 
treatment response. The neurocognitive battery was by design very brief to allow for across site data 
collection; therefore, we did not assay broader domains such as creativity and we cannot draw any 
conclusions outside of the core cognitive tests assessed. Although to our knowledge this is the largest 
cohort of BD patients with both information on lithium treatment and cognitive data, our follow up 
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longitudinal analyses focused on lithium monotherapy were carried out in a relatively small sample 
(n=88). Most critically, we did not have cognitive testing available at a second time-point in those 
patients who did not clinically respond to lithium, so we are only able to comment on lithium’s effects in 
lithium responders.  Larger-scale, controlled trials are warranted to confirm our results. 
 
There is ample evidence from prior work that lithium acts in the brain in a largely beneficial manner to 
protect neurons from toxicity and to promote new cell growth. Anecdotal evidence has suggested 
counterintuitive deleterious effects on cognition; however, very few systematic studies have been done 
to directly address this. Our data from cross-sectional and longitudinal analyses suggest that lithium may 
be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not 
seem to significantly impair cognition when used therapeutically. This may have important implications 
to clinicians as they discuss with their patients the pros and cons of this agent in mood stabilization. 
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Figure 1. Cognitive performance at baseline of bipolar disorder patients taking lithium (N=169) vs those 
not taking lithium (N=93) were compared across six neurocognitive tests (CVLT trials 1-5, CVLT delayed 
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recall, Digit Symbol, COWAT, TMT-A and TMT-B) and a global cognitive index. Scores are expressed as z-
scores with a mean of 0 and standard deviation of 1 and were calculated within the BD sample. Error 
bars are depicted to describe variability of the data.   
 
Figure 2. Performance across six cognitive tests and global cognitive index was compared across bipolar 
disorder patients grouped according their lithium treatment regimen at baseline: a) not currently on 
lithium (NCL; N=93); b) currently on lithium but unstable (CLU; N=52); c) currently on lithium 
polytherapy (CLP; N=44); d) currently on lithium monotherapy (CLM; N=73). Z-scores (with mean of zero 
and standard deviation of 1) are used. Error bars are depicted to describe variability of the data.   
 
Figure 3. Change in performance (of a subset of the entire cohort) from baseline to follow-up on the six 
neurocognitive tests (CVLT trials 1-5, CVLT delayed recall, Digit Symbol, COWAT, TMT-A and TMT-B) and 
a global cognitive index in BD subjects taking lithium is reported. Z-scores (with mean of 1 and standard 
deviation of 1) and calculated within the BD sample are used. * indicates p<0.05.  
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Table 1. Group baseline comparisons between patients that were on lithium (Li+yes) and those who were not on lithium (Li+no)  







  N (%) N (%)   
Sex: Male 45 (48.4) 76 (45.0)  X2(1)=0.3 0.6 
 Female 48 (51.6) 93 (55.0)   
Race: White 66 (71.0) 150 (88.8) X2(1)=13.1 <0.001 
 Non-white 27 (29.0) 19 (11.2)   
  Mean (SD) Mean (SD)   
Age  38.9 (12.1) 44.7 (15.3) F(1,264)=10.0 0.002 
Manic Symptoms (CARS-M)  8.2 (6.4) 3.9 (6.9) F(1,256)=24.7 <0.001 
Depressive Symptoms (MADRS)  19.7 (11.5) 7.6 (8.8) F(1,261)=90.3 <0.001 
Premorbid IQ (WRAT-3)      
Cognitive Tests      
CVLT trials 1-5  47.0 (12.8) 48.8 (12.5)  F(1,256)=1.2 0.3 
CVLT delayed recall  9.9 (3.7) 9.9 (3.5) F(1,255)=0.007 0.9 
Digit Symbol  63.0 (17.1) 60.4 (16.8) F(1,260)=1.4 0.2 
WRAT   103.1 (13.6) 105.7 (10.5) F(1,241)=2.7 0.1 
COWAT  38.3 (10.8) 39.3 (11.6) F(1,257)=0.5 0.5 
TMT-A  30.2 (13.3) 32.8 (12.5) F(1,258)=2.5 0.1 
TMT-B  80.1 (41) 81.5 (41.6) F(1,254)=0.07 0.8 




Fig1. Performance at baseline of Bipolar Disorder patients on lithium (169) vs those not on lithium (N=93) across the 6 






Fig 2. Performance across the six neurocognitive tests and a general composite score of Bipolar Disorder patients grouped 
according their lithium treatment regimen at baseline: a) Not Currently on Lithium (NCL; N=93); b) Currently on Lithium but 
Unstable (CLU; N=52); c) Currently on Lithium Polytherapy (CLP; N=44); d) Currently on Lithium Monotherapy (CLM; N=73).  





Fig 3. Change in performance from baseline to follow-up on cognitive tests in Bipolar Disorder subjects on a lithium 
monotherapy 
 
 
